Imlunestrant

Brand names: Inluriyo · Active ingredient: Imlunestrant

In short: INLURIYO is indicated: as monotherapy, for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression

Forms & strengthsINLURIYO tablets contain 200 mg imlunestrant and are white, film coated-capsule-shaped tablets, with “LILLY” on one side and “1717” and elongated 4-point starburst on the other side.
LabelEli Lilly and Company
Label updatedOct 01, 2026

What is Imlunestrant used for?

INLURIYO is indicated:

as monotherapy, for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy .

in combination with abemaciclib for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy .

Imlunestrant dosage

Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with INLURIYO based on the presence of ESR1 mutation(s) in a plasma specimen using an FDA-authorized test .

Information on FDA-authorized tests for the detection of ESR1 mutations in breast cancer is available at: https://www.fda.gov/CompanionDiagnostics.

The recommended dosage of INLURIYO, as monotherapy or in combination with abemaciclib, is 400 mg orally once daily until disease progression or unacceptable toxicity.

Take on an empty stomach at least 2 hours before food or 1 hour after food . Take INLURIYO tablets at approximately the same time daily. Swallow the tablets whole. Do not split, crush, or chew the tablets.

If patient misses a dose by 6 or more hours or vomits, instruct the patient to take the next dose the following day at its scheduled time.

Refer to the Prescribing Information for the recommended dosage of abemaciclib when used in combination with INLURIYO.

The recommended INLURIYO dosage modifications for adverse reactions are provided in Tables 1 and 2.

The recommended dose reduction is to 200 mg once daily.

Permanently discontinue INLURIYO in patients who are unable to tolerate 200 mg once daily.

Refer to the Prescribing Information for dosage modification guidelines and other relevant safety information for abemaciclib when used in combination with INLURIYO.

Grade | INLURIYO Dosage Modifications

Persistent or recurrent Grade 2 that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1 | Withhold until toxicity resolves to baseline or ≤Grade 1.

Resume INLURIYO at the same dose.

Grade 3 or 4 (except non-hepatic asymptomatic laboratory changes) | Withhold until toxicity resolves to baseline or ≤Grade 1.

Resume INLURIYO at next lower dose.

Abbreviation: ALT = alanine aminotransferase, AST = aspartate aminotransferase, TBL=total bilirubin, ULN = upper limit of normal.

Monitor ALT/AST during imlunestrant therapy as clinically indicated.

Liver Transaminase | INLURIYO Dosage Modifications

Persistent or Recurrent:

AST/ALT >3.0-5.0Ă—ULN | Withhold until toxicity resolves to baseline or to >ULN-3.0Ă—ULN.

Resume INLURIYO at the same dose.

If AST/ALT at baseline is within the normal range:

AST/ALT >5.0-20Ă—ULNOr

If AST/ALT at baseline is above ULN:

AST/ALT ≥3 × baseline (if AST/ALT≥1.5 x ULN at baseline)OrAST/ALT >8 × ULN(whichever is the lower threshold) | Withhold until toxicity resolves to baseline or to >ULN-3.0×ULN.

Resume INLURIYO at next lower dose or discontinue if receiving 200 mg daily. …

How to take Imlunestrant — instructions & advice from the label

Advise patients to read the FDA-approved patient labeling (Patient Information).

Dyslipidemia

Advise patients that hypercholesterolemia and hypertriglyceridemia may occur while taking INLURIYO. Inform patients that lipid profile monitoring will be performed prior to starting and periodically while taking INLURIYO .

Embryo-Fetal Toxicity

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy .

Advise females of reproductive potential to use effective contraception during treatment with INLURIYO and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with INLURIYO and for 1 week after the last dose .

Refer to the Prescribing Information of abemaciclib when administered in combination with INLURIYO for pregnancy and contraception information. When used in combination, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of the individual products. …

Warnings & precautions

Do not take this medicine if: None.

Based on findings in animals and its mechanism of action, INLURIYO can cause fetal harm when administered to a pregnant woman. In an animal reproduction study, oral administration of imlunestrant to pregnant rats during the period of organogenesis led to embryo-fetal mortality and structural abnormalities at maternal exposures that were below the human exposure at the recommended dose based on AUC.

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with INLURIYO and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with INLURIYO and for 1 week after the last dose .

Imlunestrant side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

ER+, HER2-,

ESR1

-mutated Advanced or Metastatic Breast Cancer

INLURIYO as Monotherapy

The safety of INLURIYO was evaluated in 651 patients with ER+, HER2- locally advanced or metastatic breast cancer previously treated with endocrine therapy with or without a prior CDK4/6 inhibitor in EMBER-3 . Patients received INLURIYO 400 mg orally, once daily (n=327), or standard of care (n=324) consisting of either fulvestrant (n=292) or exemestane (n=32). Among patients who were treated with INLURIYO, the median duration of exposure was 5.6 months (range: 0.2 to 28.6 months) in EMBER-3.

Serious adverse reactions occurred in 10% of patients who received INLURIYO. Serious adverse reactions in > 1% of patients included pleural effusion (1.2%). Fatal adverse reactions occurred in 1.8% of patients who received INLURIYO, including cardiac arrest, acute myocardial infarction, right ventricular failure, hypovolemic shock, and upper gastrointestinal hemorrhage (each 0.3%).

Permanent treatment discontinuation of INLURIYO due to an adverse reaction occurred in 4.6% of patients. …

Drug interactions

Strong CYP3A Inhibitors

Avoid concomitant use of INLURIYO with strong CYP3A inhibitors. If concomitant use cannot be avoided, reduce the dosage of INLURIYO .

Imlunestrant is a CYP3A substrate. Concomitant use of a strong CYP3A inhibitor increases imlunestrant exposure , which may increase the risk of INLURIYO-associated adverse reactions.

Strong CYP3A Inducers

Avoid concomitant use of INLURIYO with strong CYP3A inducers. If concomitant use cannot be avoided, increase the dosage of INLURIYO .

Imlunestrant is a CYP3A substrate. Concomitant use of a strong CYP3A inducer decreases imlunestrant exposure , which may reduce effectiveness of INLURIYO.

P-gp or BCRP Substrates

Avoid concomitant use unless otherwise recommended in the Prescribing Information for P-gp or BCRP substrates where minimal concentration changes may lead to serious adverse reactions.

Imlunestrant inhibits both P-gp and BCRP. Imlunestrant increases exposure of P-gp and BCRP substrates, which may increase the risk of adverse reactions related to these substrates .

About this medicine

INLURIYO tablets contain imlunestrant, an estrogen receptor antagonist. The chemical name for imlunestrant tosylate is (5R)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-(1)benzopyrano(4,3-c)quinolin-2-ol, tosylate salt (1:1). Imlunestrant tosylate is a white to practically white to yellow powder with the empirical formula C29H24F4N2O3.C7H8O3S and a molecular weight 696.71 g/mol. The aqueous solubility of imlunestrant tosylate is slightly soluble at low pH, insoluble at neutral pH, and sparingly soluble at high pH. The chemical structure of imlunestrant tosylate is shown below:

INLURIYO tablets are for oral administration. Each INLURIYO tablet is available as capsule-shaped, film-coated tablet that contains 200 mg imlunestrant (equivalent to 265.66 mg imlunestrant tosylate). The tablet contains the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, and microcrystalline cellulose. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5bc172e4-e8a2-441a-be52-279a7f890196. Read the full official label on DailyMed.

Related medicines

Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone